Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
Revenue
Antisense Therapeutics Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Antisense Therapeutics Ltd
ASX:ANP
|
Revenue
AU$384.9k
|
CAGR 3-Years
133%
|
CAGR 5-Years
72%
|
CAGR 10-Years
6%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$190.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$237.6m
|
CAGR 3-Years
550%
|
CAGR 5-Years
77%
|
CAGR 10-Years
47%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$588.4k
|
CAGR 3-Years
56%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$11.7m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Antisense Therapeutics Ltd's Revenue?
Revenue
384.9k
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Revenue amounts to 384.9k AUD.
What is Antisense Therapeutics Ltd's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 1 026%. The average annual Revenue growth rates for Antisense Therapeutics Ltd have been 133% over the past three years , 72% over the past five years , and 6% over the past ten years .